Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Herbs, menopause, and dialysis.

Beatrix Roemheld-Hamm1, Naomi V Dahl

  • 1Department of Family Medicine, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick, New Jersey 08901, USA. hammbr@umdnj.edu

Seminars in Dialysis
|March 5, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hypophosphatemia Associated with Intravenous Iron Therapies for Iron Deficiency Anemia: A Systematic Literature Review.

Therapeutics and clinical risk management·2020
Same author

Ferumoxytol for iron deficiency anemia in patients undergoing hemodialysis. The FACT randomized controlled trial
.

Clinical nephrology·2019
Same author

Correction to: The Ferumoxytol for Anemia of CKD Trial (FACT)-a randomized controlled trial of repeated doses of ferumoxytol or iron sucrose in patients on hemodialysis: background and rationale.

BMC nephrology·2018
Same author

Efficacy and safety of IV ferumoxytol for iron deficiency anemia in patients with cancer.

Journal of blood medicine·2017
Same author

Cost-effectiveness analysis of intravenous ferumoxytol for the treatment of iron deficiency anemia in adult patients with non-dialysis-dependent chronic kidney disease in the USA.

ClinicoEconomics and outcomes research : CEOR·2017
Same author

The Ferumoxytol for Anemia of CKD Trial (FACT)-a randomized controlled trial of repeated doses of ferumoxytol or iron sucrose in patients on hemodialysis: background and rationale.

BMC nephrology·2017

Women with chronic kidney disease (CKD) face gynecologic and reproductive health issues. This review examines the safety and efficacy of popular herbal medicines for CKD patients on dialysis.

Area of Science:

  • Nephrology and Women's Health
  • Integrative and Complementary Medicine

Background:

  • Women with chronic kidney disease (CKD) experience higher rates of menstrual irregularities, premature menopause, and osteoporosis.
  • Gynecologic and reproductive health concerns are often undiscussed between CKD patients and their nephrologists.
  • Complementary and alternative medicine (CAM) products are frequently explored by women with end-stage renal disease (ESRD) for these conditions.

Observation:

  • Limited data exists on the safe and effective use of herbal medicines by patients undergoing chronic dialysis.
  • This poses challenges for both patients and healthcare providers in assessing the quality, safety, and efficacy of botanical products.
  • Key herbal supplements of interest include black cohosh, ginseng, chastetree, dong quai, and evening primrose oil, alongside soy products and natural hormones.

Related Experiment Videos

Findings:

  • This article critically reviews the available scientific evidence on the safety and efficacy of specific herbal medicines commonly used by women with CKD.
  • It discusses crucial pharmacologic parameters for evaluating the quality of botanical products.
  • Recommendations and resources for informed decision-making are provided.

Implications:

  • Highlights the need for evidence-based guidance on CAM use in CKD patients.
  • Empowers patients and clinicians with information to navigate the use of herbal products safely.
  • Addresses a critical knowledge gap in managing the holistic health needs of women with kidney disease.